Novartis aims to pump up cardio business with Ionis deal

Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.

from Reuters: Health News https://ift.tt/2GMYnUe